Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $9.75
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
Daily · Wilder smoothing
| Jun 30, 26 |
| Citizens |
| maintain |
| Market Outperform |
| Market Outperform |
| May 4, 26 | Guggenheim | maintain | Buy | Buy |
| May 1, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| Mar 27, 26 | Guggenheim | maintain | Buy | Buy |
| Mar 27, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| Dec 17, 25 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Dec 17, 25 | Citizens | maintain | Market Outperform | Market Outperform |
| Dec 17, 25 | Guggenheim | maintain | Buy | Buy |
| Dec 17, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 39.85 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 48.84 | Oscillator | Neutral |
| Williams %R (14) | -44.83 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.73 (Hist 0.14) | Oscillator | Buy |
| Average Directional Index (14) | 36.04 (+DI 18.1 / -DI 28.6) | Trend | Strong Sell |
| EMA 20 | 10.05 | MA | Strong Sell |
| SMA 20 | 9.97 | MA | Sell |
| EMA 50 | 11.56 | MA | Strong Sell |
| SMA 50 | 11.96 | MA | Strong Sell |
| SMA 200 | 17.13 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jul 29, 26 | Mohideen Pharis | officer: Chief Medical Officer | S-Sale | 464 @ $2.70 | $1.25K |
| Oct 30, 25 |
| Lee Philina |
| 0 |
| — |
| Jan 29, 26 | Mohideen Pharis | officer: Chief Medical Officer | S-Sale | 534 @ $4.86 | $2.60K |
| Jan 12, 26 | Baker Bros. Advisors Lp | director | M-Exempt | 25,005,240 | — |
| Jan 12, 26 | Baker Bros. Advisors Lp | director | M-Exempt | 2,299,656 | — |
| Jan 12, 26 | Baker Bros. Advisors Lp | director | M-Exempt | 25,005,240 | — |
| Dec 17, 25 | Epic Bpifrance | other: Member of 10% owner group | S-Sale | 2,036,990 @ $4.84 | $9.86M |
| Dec 17, 25 | Epic Bpifrance | other: Member of 10% owner group | S-Sale | 40,000 @ $5.28 | $211.2K |
TTM vs. 5-year historical average (annual ratios)
| Metric | DBVT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -2.5x | -9.5x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -13.0x | EPS est. -0.75 | Elevated |
| Price / Book | 5.2x | 8.4x | Discount |
| Price / Sales | 56.8x | 91.3x | Discount |
| EV / EBITDA | -1.0x | -9.1x | Discount |
| Return on equity | -119.5% | — | Weak |
| Gross margin | -122.2% | 23.6% | Below hist. |
| Debt / Equity | 0.14 | 0.12 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -1.38 | Distress |
Discounted cash flow model
Stock news · updated daily
DBV Technologies (NASDAQ: DBVT - Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ: ARWR - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations. Risk and Volatility DBV Technologies has a beta
DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $8.90 and last traded at $9.03, with a volume of 344,103 shares traded. The stock had previously closed at $9.55. Analyst Ratings Changes A number of equities research analysts have
Shares of DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) hit a new 52-week low on Thursday. The company traded as low as $9.64 and last traded at $9.77, with a volume of 535276 shares changing hands. The stock had previously closed at $9.98. Analysts Set New Price Targets A number of brokerages have issued
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 16, 2026 | -0.12 | -0.14 | Miss -14.4% | $800.9K |
| Apr 30, 2026 | -0.14 | -0.56 | Miss -300.0% | $1.06M |
| Mar 27, 2026 | -1.30 | -1.15 | Beat 11.5% | $574.6K |
| Oct 28, 2025 | -1.45 | -0.34 | Beat 76.3% | $3.23M |
| Jul 30, 2025 | -0.21 | -1.55 | Miss -638.1% | $1.74M |
| Apr 30, 2025 | -0.24 | -0.26 | Miss -8.3% | $800.0K |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Sep 30, 2026 | 2026-09-29 21:18:49 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 16:03:20 | View |
| SC 13G | Aug 6, 2026 | 2026-08-06 17:50:00 | View |
| 4 | Jul 31, 2026 | 2026-07-31 16:15:05 | View |
| S-3ASR | Jul 27, 2026 | 2026-07-27 07:46:26 | View |
| 8-K | Jul 16, 2026 | 2026-07-16 17:02:04 | View |
| 10-Q | Jul 16, 2026 | 2026-07-16 16:08:51 | View |
| 8-K | Jun 29, 2026 | 2026-06-29 16:28:49 | View |
| 8-K | Jun 5, 2026 | 2026-06-05 16:01:38 | View |
| S-8 | Jun 4, 2026 | 2026-06-04 16:03:22 | View |
Proxy statement (DEF 14A) disclosures